Three announcements in the last week helped propel Rohr Industries 1 7/8 to 34 3/4, according to Irving Katz, director of research for San Diego Securities.
During an interview with Dow Jones, Rohr forecast a 21% increase in annual sales to $800 million. Rohr expects earnings to rise by 34% to 44%.
The company also announced that it would purchase Fairchild's composite bonding center in Hagerstown, Md., for an undisclosed amount. Last week the company filed for $100 million in convertible debentures.
Molecular Biosystems made a new high of 15 1/2 and closed the week up 2 1/8 to 14 1/8 on the announcement that the Food & Drug Administration would treat its Albunex ultrasound contrast imaging agent as a medical device. That classification could ultimately lead to more rapid market approval, Katz said.